An interventional study of Continuous positive airway pressure and Niacin in Sleep Apnea and Pre-diabetes, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by University of Chicago · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 369 studies in Sleep Apnea Syndromes with a site in United States — 49 open to participants now, 60 under way, 3 of them phase 3. Sleep Apnea Syndromes · United States.
Among the 369 studies in Sleep Apnea Syndromes with a site in United States, this one is the 197th largest by enrollment of the 284 interventional ones that give a count, is one of 22 that started in 2019, is one of 193 with no phase, and was the 266th registered.
1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.
Browse Sleep Apnea Syndromes studies →49 of the 369 studies in Sleep Apnea Syndromes with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–75
Pfizer · Sites in United States
Ages 18+
Pfizer · Sites in United States
Ages 18+
VA Office of Research and Development · Sites in United States
Ages 18+ · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.
This study: 20 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
369 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 44 · Phase 3 21 · Phase 4 20
First in 1998; this study’s year is marked. 22 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 60 across 674 interventional studies indexed under Sleep Apnea Syndromes.
Median enrollment 62 across the 284 interventional studies, 114 across the 82 observational. Of the 268 that completed or were terminated, 134 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
82 of 369 have an industry lead sponsor. The 10 most frequent:
University of Chicago is the lead sponsor of 926 studies on the registry; 187 are open to participants now.
Of its 103 completed or terminated interventional studies of FDA-regulated products, 72 (70%) have results posted.
University of Chicago has 6 studies filed under Sleep Apnea Syndromes — fewer than ten, so there is no comparison to draw.
30 of the studies in Sleep Apnea Syndromes with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07613281Serene Sleep, Inc.Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA). | 2026-11 |
| NCT05382754Children's Hospital of PhiladelphiaHome Apnea Testing in CHildren Trial | 2026-12 |
| NCT05575401Loma Linda UniversityLateral Pharyngoplasty Outcomes in Children Undergoing Tonsillectomy | 2026-12 |
| NCT02431507Michael HarrisonMagnetic Apnea Prevention(MAGNAP) Device to Treat Obstructive Sleep Apnea:First-In-Human Study of Feasibility and Safety | 2026-12-01 |
| NCT07908199Ouraring Inc.Oura Ring OA15 Validation | 2026-12-03 |
Add all 30 to your calendar (.ics) → With an account.
Among the 369 studies in Sleep Apnea Syndromes with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.
Substantial evidence indicates that obstructive sleep apnea (OSA) is associated with impaired glucose metabolism, however, metabolic mechanisms underlying this association remain unclear. This mechanistic study will determine systemic and cellular metabolic pathways that contribute to impaired glucose metabolism in obstructive sleep apnea (OSA). Understanding of how obstructive sleep apnea (OSA) affects glucose metabolism may help identify novel targets for risk prediction and/or treatment of metabolic impairments beyond continuous positive airway pressure (CPAP). Obstructive sleep apnea (OSA) patients with prediabetes will be studied under three in-laboratory conditions in a randomized cross-over design: untreated condition (obstructive sleep apnea), treated condition (continuous positive airway pressure), untreated but pharmacologically suppressed lipolysis condition (Niacin). The investigator will perform whole body and cellular assessments under each study condition.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Untreated condition (obstructive sleep apnea)
Continuous positive airway pressure (CPAP) treatment
Device: Continuous positive airway pressure
Untreated, pharmacological suppression of lipolysis by Niacin
Other: Niacin
Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)
Also known as: CPAP
Suppression of lipolysis by niacin infusion
Also known as: Suppression of lipolysis by niacin infusion
Insulin Sensitivity
Insulin sensitivity is calculated from a model fitted to blood glucose using insulin and C-peptide values measured during a glucose tolerance test
Time frame: Untreated, within 4 months of screening
Insulin Sensitivity
Insulin sensitivity is calculated from a model fitted to blood glucose using insulin and C-peptide values measured during a glucose tolerance test
Time frame: CPAP, within 4 months of screening
Insulin Sensitivity
Insulin sensitivity is calculated from a model fitted to blood glucose using insulin and C-peptide values measured during a glucose tolerance test
Time frame: Niacin, within 4 months of screening
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2019 to primary completion in Jul 2026, 80 months.
Of 202 non-industry interventional studies with no phase under Sleep Apnea Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 60. This study's 80 months is above that.
Counting every sponsor, half of 271 studies reached it within 26 months; a quarter within 11 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.